New approaches for pediatric rhabdomyosarcoma drug discovery: targeting combinatorial signaling

Bibliography

• Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975 – 1999. Cancer 2008;113(9):2575-96
   PubMed Web of Science ®Google Scholar
• Pappo AS, Shapiro DN, Crist WM, Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13(10):2123-39
   PubMedGoogle Scholar
• Landier W, Bhatia S. Cancer survivorship: a pediatric perspective. Oncologist 2008;13(11):1181-92
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Linabery AM, Charbonneau B, Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975 – 2005. Cancer 2009;115(18):4218-26
   PubMed Web of Science ®Google Scholar
• Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20(40):5736-46
   PubMed Web of Science ®Google Scholar
• Galili N, Davis RJ, Fredericks WJ, Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nature 1993;5(3):230-5
   Web of Science ®Google Scholar
• Xia SJ, Barr FG. Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors. Eur J Cancer 2005;41(16):2513-27
   PubMed Web of Science ®Google Scholar
• Davis RJ, D'Cruz CM, Lovell MA, Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54(11):2869-72
   PubMed Web of Science ®Google Scholar
• Sorensen PH, Lynch JC, Qualman SJ, PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002;20(11):2672-9
   PubMed Web of Science ®Google Scholar
• Kazanowska B, Reich A, Stegmaier S, PAX3–FKHR and PAX7–FKHR fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal Pediatr Pathol 2007;26(1):17-31
   PubMed Web of Science ®Google Scholar
• Barr FG, Qualman SJ, Macris MH, Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 2002;62(16):4704-10
   PubMed Web of Science ®Google Scholar
• Wachtel M, Dettling M, Koscielniak E, Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004;64:5539-45
   PubMed Web of Science ®Google Scholar
• Sumegi J, Streblow R, Frayer RW. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010;49(3):224-36
   PubMed Web of Science ®Google Scholar
• Anderson J, Gordon A, McManus A, Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999;1(4):340-8
   PubMedGoogle Scholar
• Smith AC, Choufani S, Ferreira JC, Growth regulation, imprinted genes, and chromosome 11p15.5. Pediatr Res 2007;61(5 Pt 2):43R-7R
   PubMed Web of Science ®Google Scholar
• Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94(1):445-8
   PubMed Web of Science ®Google Scholar
• Visser M, Sijmons C, Bras J, Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997;15(11):1309-14
   PubMed Web of Science ®Google Scholar
• Maurer HM, Beltangady M, Gehan EA, The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin Pharmacother 2011;12(4):517-31
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Boos J, Beske F, Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high-dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 2008;50:739-45
   PubMed Web of Science ®Google Scholar
• Huh WW, Skapek XS. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010;12:402-10
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Lyden E, Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from the United States and European Cooperative Groups. J Clin Oncol 2008;26:2384-9
   PubMed Web of Science ®Google Scholar
• Melcon SG, de Toledo Codina JS. Molecular biology of rhabdomyosarcoma. Clin Transl Oncol 2007;9:415-19
   PubMed Web of Science ®Google Scholar
• Hu K, Lee C, Qiu D, Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009;8(11):3024-35
   PubMed Web of Science ®Google Scholar
• Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010;36(4):318-27
   PubMed Web of Science ®Google Scholar
• Crose LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma 2011, Published online 2 January 2011;doi:10.1155/2011/756982
   Google Scholar
• Houghton PJ, Morton CL, Tucker C, The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49(7):928-40
   PubMed Web of Science ®Google Scholar
• Morton CL, Houghton PJ. The pediatric preclinical testing program. Tumor models in cancer research. Cancer Drug Discovery and Development, Humana Press 2011
   Google Scholar
• Zwaan CM, Kearns P, Caron H, The role of innovative therapies for children with cancer (ITCC) European consortium. Cancer Treat Rev 2010;36(4):328-34
   PubMed Web of Science ®Google Scholar
• Charytonowicz E, Cordon-Cardo C, Matushansky I, Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett 2009;279(2):126-36
   PubMed Web of Science ®Google Scholar
• Hettmer S, Wagers AJ. Muscling in: uncovering the origins of rhabdomyosarcoma. Nat Med 2010;16(2):171-3
   PubMed Web of Science ®Google Scholar
• Lisboa S, Cerveira N, Vieira J, Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. Pediatr Blood Cancer 2008;51(4):554-7
   PubMed Web of Science ®Google Scholar
• Shinkoda Y, Nagatoshi Y, Fukano R, Rhabdomyosarcoma masquerading as acute leukemia. Pediatr Blood Cancer 2009;52(2):286-7
   PubMed Web of Science ®Google Scholar
• Bober E, Lyons GE, Braun T, The muscle regulatory gene, Myf-6, has a biphasic pattern of expression during early mouse development. J Cell Biol 1991;113(6):1255-65
   PubMed Web of Science ®Google Scholar
• Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res 2005;65(17):7530-2
   PubMed Web of Science ®Google Scholar
• Langenau DM, Keefe MD, Storer NY, Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007;21(11):1382-95
   PubMed Web of Science ®Google Scholar
• Linardic CM, Naini S, Herndon JE, The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res 2007;67(14):6691-9
   PubMed Web of Science ®Google Scholar
• Ren YX, Finckenstein FG, Abdueva DA, Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008;68(16):6587-97
   PubMed Web of Science ®Google Scholar
• Rubin BP, Nishijo K, Chen HI, Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011;19(2):177-91
   PubMed Web of Science ®Google Scholar
• Das B, Tsuchida R, Malkin D, Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008;26:1818-30
   PubMed Web of Science ®Google Scholar
• Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5(7):738-43
   PubMed Web of Science ®Google Scholar
• Hirotsu M, Setoguchi T, Matsunoshita Y, Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer 2009;101(12):2030-7
   PubMed Web of Science ®Google Scholar
• Merlino G, Khanna C. Fishing for the origins of cancer. Genes Dev 2007;21(11):1275-9
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Pontoglio A, Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther 2011;11(7):875-92
   PubMed Web of Science ®Google Scholar
• Walter D, Satheesha S, Albrecht P, CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 2011;6(5):e19506
   PubMedGoogle Scholar
• Takenobu H, Shimozato O, Nakamura T, CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011;30(1):97-105
   PubMed Web of Science ®Google Scholar
• McCabe C, Smyth J. How to improve the cost effectiveness of oncology drug development: a commentary on Tan et al. Anti-cancer drug resistance – Understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 2010;46(12):2143-4
   PubMed Web of Science ®Google Scholar
• Melguizo C, Prados J, Rama AR, Multidrug resistance and rhabdomyosarcoma. Oncol Rep 2011;26(4):755-61
   PubMed Web of Science ®Google Scholar
• Lee AJ, Kolesnick R, Swanton C. RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Rev Mol Med 2009;11:e15
   PubMed Web of Science ®Google Scholar
• Tan DS, Gerlinger M, Teh BT, Swanton C. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 2010;46(12):2166-77
   PubMed Web of Science ®Google Scholar
• Juul N, Szallasi Z, Eklund AC, Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010;11(4):358-65
   PubMed Web of Science ®Google Scholar
• Schaaf GJ, Ruijter JM, van Ruissen F, Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J 2005;19(3):404-6
   PubMedGoogle Scholar
• De Pitta C, Tombolan L, Albiero G, Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 2006;118(11):2772-81
   PubMed Web of Science ®Google Scholar
• Davicioni E, Finckenstein FG, Shahbazian V, Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;66(14):6936-46
   PubMed Web of Science ®Google Scholar
• Goldstein M, Meller I, Issakov J, Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia 2006;8(5):332-43
   PubMed Web of Science ®Google Scholar
• Romualdi C, De Pitta C, Tombolan L, Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genomics 2006;7:287
   PubMed Web of Science ®Google Scholar
• Lae M, Ahn EH, Mercado GE, Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. Pathology 2007;212(2):143-51
   Web of Science ®Google Scholar
• Missiaglia E, Selfe J, Hamdi M, Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 2009;48(6):455-67
   PubMed Web of Science ®Google Scholar
• Davicioni E, Anderson MJ, Finckenstein FG, Molecular classification of rhabdomyosarcoma–genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009;174(2):550-64
   PubMed Web of Science ®Google Scholar
• Williamson D, Missiaglia E, de Reynies A, Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010;28(13):2151-8
   PubMed Web of Science ®Google Scholar
• Kurmasheva R, Hosoi H, Kikuchi K, Molecular therapy for Rhabdomyosarcoma. Molecularly Targeted Therapy for Childhood Cancer. Springer 2010
   Google Scholar
• Tomescu O, Xia SJ, Strezlecki D, Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest 2004;84(8):1060-70
   PubMed Web of Science ®Google Scholar
• Ebauer M, Wachtel M, Niggli FK, Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007;26(51):7267-81
   PubMed Web of Science ®Google Scholar
• Cao L, Yu Y, Bilke S, Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010;70(16):6497-508
   PubMed Web of Science ®Google Scholar
• Naini S, Etheridge KT, Adam SJ, Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008;68(23):9583-8
   PubMed Web of Science ®Google Scholar
• Bernasconi M, Remppis A, Fredericks WJ, Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 1996;93(23):13164-9
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Tsuchiya K, Otabe O, Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008;365(3):568-74
   PubMed Web of Science ®Google Scholar
• Mercado GE, Xia SJ, Zhang C, Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 2008;47(6):510-20
   PubMed Web of Science ®Google Scholar
• Li HG, Wang Q, Li HM, PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. Cancer Lett 2007;253(2):215-23
   PubMed Web of Science ®Google Scholar
• Nabarro S, Himoudi N, Papanastasiou A, Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J Exp Med 2005;202(10):1399-410
   PubMed Web of Science ®Google Scholar
• Onisto M, Slongo ML, Gregnanin L, Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005;27(3):791-8
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Mizuguchi M, Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer 2007;46(4):348-58
   PubMed Web of Science ®Google Scholar
• Linardic CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 2008;270(1):10-18
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313(5795):1929-35
   PubMed Web of Science ®Google Scholar
• Iorns E, Lord CJ, Turner N, Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6(7):556-68
   PubMed Web of Science ®Google Scholar
• Hu K, Lee C, Qiu D, Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009;8(11):3024-35
   PubMed Web of Science ®Google Scholar
• Sarver AL, Phalak R, Thayanithy V, S-MED: sarcoma microRNA expression database. Lab Invest 2010;90:753-61
   PubMed Web of Science ®Google Scholar
• Rosenfeld N, Aharonov R, Meiri E, MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-9
   PubMed Web of Science ®Google Scholar
• Subramanian S, Lui WO. Lee Ch, et al. MicroRNA expression signature of human sarcomas. Oncogene 2008;27(14):2015-26
   PubMed Web of Science ®Google Scholar
• Ciarapica R, Russo G, Verginelli F, Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009;8(1):172-5
   PubMed Web of Science ®Google Scholar
• Kim HK, Lee YS, Sivaprasad U, Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006;174(5):677-87
   PubMed Web of Science ®Google Scholar
• Wang H, Garzon R, Sun H, NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008;14(5):369-81
   PubMed Web of Science ®Google Scholar
• Taulli R, Bersani F, Foglizzo V, The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009;119(8):2366-78
   PubMed Web of Science ®Google Scholar
• Yan D, Dong Xda E, Chen X, MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009;284(43):29596-604
   PubMed Web of Science ®Google Scholar
• Pisantia S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 2009;60(2):107-16
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Afaq F, Adhami VM, Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006;281(51):39480-91
   PubMed Web of Science ®Google Scholar
• Oesch S, Walter D, Wachtel M, Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 2009;8(7):1838-45
   PubMed Web of Science ®Google Scholar
• Gustafsson SB, Lindgren T, Jonsson M, Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 2009;63(4):691-701
   PubMed Web of Science ®Google Scholar
• Liu WM, Scott KA, Shamash J, Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma 2008;49(9):1800-9
   PubMed Web of Science ®Google Scholar
• Pui CH, Gajjar AJ, Kane JR, Challenging issues in pediatric oncology. Nat Rev Clin Oncol 2011; Published online 28 June 2011, doi: 10.1038/nrclinonc.2011.95
   PubMedGoogle Scholar
• Martins AS, Olmos D, Missiaglia E, Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011;2011:209736
   PubMedGoogle Scholar
• Wan X, Harkavy B, Shen N, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26(13):1932-40
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Dudkin L, Billups C, The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
   PubMed Web of Science ®Google Scholar
• Jouaux EM, Schmidtkunz K, Muller KM, Targeting the c-Myc coiled coil with interfering peptides. J Pept Sci 2008;14(9):1022-31
   PubMed Web of Science ®Google Scholar
• Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006;5:31
   PubMed Web of Science ®Google Scholar
• Marampon F, Bossi G, Ciccarelli C, MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 2009;8(3):543-51
   PubMed Web of Science ®Google Scholar
• Marampon F, Gravina GL, Di Rocco A, MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 2011;10(1):159-68
   PubMed Web of Science ®Google Scholar
• Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010;9:75
   PubMed Web of Science ®Google Scholar
• Kummar S, Chen HX, Wright J, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010;9(11):843-56
   PubMed Web of Science ®Google Scholar
• Abraham J, Prajapati SI, Nishijo K, Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther 2011;10(4):697-707
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Maris JM, Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Dong J, Demarest SJ, Sereno A, Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010;9(9):2593-604
   PubMed Web of Science ®Google Scholar
• De Giovanni C, Landuzzi L, Nicoletti G, Molecular and cellular biology of rhabdomyosarcoma. Future Oncol 2009;5(9):1449-75
   PubMed Web of Science ®Google Scholar
• Baguley B, Marshall E. The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs. Expert Opin Drug Discov 2008;3(2):153-61
   PubMed Web of Science ®Google Scholar
• Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130(4):601-10
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC, Van Tilborg AA, Eijk PP, The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008;27(14):2091-6
   PubMed Web of Science ®Google Scholar
• Friedrich J, Seidel C, Ebner R, Spheroid-based drug screen: considerations and practical approach. Nat Protocol 2009;4(3):309-24
   PubMed Web of Science ®Google Scholar
• Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 2009;19(1):132-43
   PubMed Web of Science ®Google Scholar
• Hait WN. Anticancer drug development: the grand challenges. Nat Rev Drug Discov 2010;9(4):253-4
   PubMed Web of Science ®Google Scholar
• Lucas M, Louis C, Darren H, Preclinical drug development for childhood cancer. Expert Opin Drug Discov 2011;6(1):49-64
   PubMed Web of Science ®Google Scholar
• Heyer J, Kwong LN, Lowe SW, Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010;10(7):470-80
   PubMed Web of Science ®Google Scholar
• Taylor BS, Barretina J, Maki RG, Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011;11:541-57
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19(12):3091-102
   PubMed Web of Science ®Google Scholar
• Raney RB, Maurer HM, Anderson JR, The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I Through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001;5(1):9-15
   PubMedGoogle Scholar
• Raney B, Anderson J, Arndt C, Primary renal sarcomas in the intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972 – 2005: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:339-43
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Praquin MT, Non metastatic rhabdomyosarcoma (RMS): Outlines for the SIOP MMT 95 study. Med Pediatr Oncol 1996;27:265
   Google Scholar
• Stevens M, Rey A, Bouvet N, Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the international society of paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23(12):2618-28
   PubMed Web of Science ®Google Scholar
• McDowell HP, Foot AB, Ellershaw C, Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 2010;46(9):1588-95
   PubMed Web of Science ®Google Scholar
• Orbach D, Rey A, Cecchetto G, Infantile fibrosarcoma: management based on the European experience. J Clin Oncol 2010;28(2):318-23
   PubMed Web of Science ®Google Scholar
• Koscielniak and Klingebiel - Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma (CWS-2007-HR). Available from: http://clinicaltrials.gov/ct2/show/NCT00876031 [Last accessed 31 July 2011]
   Google Scholar
• Bisogno G, Ferrari A, Bergeron C, The IVADo regimen–a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005;103(8):1719-24
   PubMed Web of Science ®Google Scholar
• Paulson V, Chandler G, Rakheja D, High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 2011;50(6):397-408
   PubMed Web of Science ®Google Scholar
• Anderson J, Ramsay A, Gould S, Pritchard-Jones K. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 2001;159(3):1089-96
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang C. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression. J Biol Chem 2003;278(1):27-36
   PubMed Web of Science ®Google Scholar
• Linardic CM, Downie DL, Qualman S, Genetic modeling of human rhabdomyosarcoma. Cancer Res 2005;65(11):4490-5
   PubMed Web of Science ®Google Scholar
• Begum S, Emami N, Cheung A, Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005;24(11):1860-72
   PubMed Web of Science ®Google Scholar
• Taulli R, Scuoppo C, Bersani F, Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66(9):4742-9
   PubMed Web of Science ®Google Scholar
• Scuoppo C, Riess I, Schmitt-Ney M, The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. Exp Cell Res 2007;313(11):2308-17
   PubMed Web of Science ®Google Scholar
• Graf Finckenstein F, Shahbazian V, Davicioni E, PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene 2008;27(14):2004-14
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schwartz J, Wang C. Comparative analysis of paired- and homeodomain-specific roles in PAX3-FKHR oncogenesis. Int J Clin Exp Pathol 2009;2(4):370-83
   PubMedGoogle Scholar
• Sharp R, Recio JA, Jhappan C, Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;8(11):1276-80
   PubMed Web of Science ®Google Scholar
• Nanni P, Nicoletti G, De Giovanni C, Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res 2003;63(11):2728-32
   PubMed Web of Science ®Google Scholar
• Fleischmann A, Jochum W, Eferl R, Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell 2003;4(6):477-82
   PubMed Web of Science ®Google Scholar
• Hahn H, Nitzki F, Schorban T, Genetic mapping of a Ptch1-associated rhabdomyosarcoma susceptibility locus on mouse chromosome 2. Genomics 2004;84:853-8
   PubMed Web of Science ®Google Scholar
• Keller C, Arenkiel BR, Coffin CM, Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004;18:2614-26
   PubMed Web of Science ®Google Scholar
• Nishijo K, Chen QR, Zhang L, Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 2009;69(7):2902-11
   PubMed Web of Science ®Google Scholar
• Seitz G, Pfeiffer M, Fuchs J, Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep 2010;24(4):1067-72
   PubMed Web of Science ®Google Scholar